← Back to Search

Aerobic Exercise for Parkinson's Disease (PDex Trial)

N/A
Recruiting
Led By Merrill Landers, DPT, PhD
Research Sponsored by University of Nevada, Las Vegas
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 minutes prior to the exercise (pre measurement) and 30 minutes after completing the 30-minute aerobic exercise condition (post measurement) . both conditions are separated by one week
Awards & highlights
No Placebo-Only Group

Summary

This trial explores how exercise can reduce inflammation in older adults and people with Parkinson's, which may slow the progression of the disease.

Who is the study for?
This trial is for people aged 30-85 with Parkinson's disease who can do 30 minutes of moderate exercise with short breaks, and healthy adults in the same age range. It excludes those with conditions like heart issues or uncontrolled blood pressure that prevent safe exercise, and those with dementia as indicated by a low score on a cognitive assessment.
What is being tested?
The study investigates how aerobic exercise might protect brain cells from dying in Parkinson's disease by reducing inflammation. Participants will engage in regular moderate aerobic exercises to see if this slows down the progression of their condition.
What are the potential side effects?
While not explicitly listed, potential side effects may include typical risks associated with moderate physical activity such as muscle soreness, fatigue, joint pain, or exacerbation of pre-existing conditions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline measurement only
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline measurement only for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Biomarkers in Parkinson Disease
Exercise and inflammatory milieu
Exercise dose and biomarkers
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: ControlActive Control1 Intervention
Older, adults who are age- and sex-matched to the PD participants.
Group II: Parkinson DiseaseActive Control1 Intervention
Participants diagnosed with Parkinson disease (PD) will the main arm of the study and will be compared to the control group.

Find a Location

Who is running the clinical trial?

University of Nevada, Las VegasLead Sponsor
73 Previous Clinical Trials
13,909 Total Patients Enrolled
1 Trials studying Dementia
113 Patients Enrolled for Dementia
Merrill Landers, DPT, PhDPrincipal InvestigatorUniversity of Nevada, Las Vegas
1 Previous Clinical Trials
300 Total Patients Enrolled

Media Library

Aerobic exercise Clinical Trial Eligibility Overview. Trial Name: NCT05854524 — N/A
Dementia Research Study Groups: Control, Parkinson Disease
Dementia Clinical Trial 2023: Aerobic exercise Highlights & Side Effects. Trial Name: NCT05854524 — N/A
Aerobic exercise 2023 Treatment Timeline for Medical Study. Trial Name: NCT05854524 — N/A
~60 spots leftby May 2026